Literature DB >> 9466986

Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase.

Ts Jeong1, S L Schissel, I Tabas, H J Pownall, A R Tall, X Jiang.   

Abstract

Apolipoprotein E knockout (apoE0) mice accumulate atherogenic remnant lipoproteins in plasma. We now provide evidence that these particles are enriched in sphingomyelin (SM), and explore the mechanisms and possible pathophysiological consequences of this finding. The phosphatidylcholine/sphingomyelin (PC/SM) ratio was reduced in all lipoproteins in apoE0 mice compared with wild-type (Wt) mice (2.0+/-0.2 vs. 4.7+/-0.5; 2.8+/-0.5 vs. 5.5+/-0.9; 1.9+/-0. 5 vs. 4.6+/-0.5 for VLDL, LDL, and HDL), reflecting 400 and 179% increases in plasma pools of SM and PC, respectively. Turnover studies using [14C]PC/[3H]SM VLDL or HDL showed that the fractional catabolic rate (FCR) of VLDL-SM and HDL-SM were markedly reduced in the apoE0 mice compared with Wt mice, while the FCRs of VLDL-PC and HDL-PC were similar. By contrast, the FCRs of [3H]PC ether and [14C]SM were identical in apoE0 and Wt mice. The production rates of VLDL-SM and HDL-SM in apoE0 mice were much higher than in Wt mice, while the production rates of lipoprotein PC were similar. To assess the underlying mechanisms, we also measured the PC/SM ratio in VLDL and LDL of LDL receptor knockout (LDLr0) and hepatic LDL receptor-related protein knockout/LDLr0 mice, but found no difference with Wt mice. Using S-sphingomyelinase, an enzyme secreted by macrophages and endothelial cells, we found that VLDL and LDL from apoE0, but not from Wt or LDLr0 mice, were significantly aggregated, and that aggregation was not prevented by adding back apoE. We then enriched the apoE0-VLDL and Wt-VLDL with different amounts of SM, and found that VLDL aggregation was enhanced. Thus, the increased SM content of lipoproteins in apoE0 mice is due to combined synthesis and clearance defects. Impaired SM clearance reflects resistance to intravascular enzymes and delayed removal by a non-LDLr, non-LDLr related protein pathway. The increased SM content in slowly cleared remnant lipoproteins may enhance their susceptibility to arterial wall SMase and increase their atherogenic potential.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466986      PMCID: PMC508639          DOI: 10.1172/JCI870

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

2.  The effect of cholesterol on the turnover of lecithin, cephalin and sphingomyelin in the rabbit.

Authors:  E L MCCANDLESS; D B ZILVERSMIT
Journal:  Arch Biochem Biophys       Date:  1956-06       Impact factor: 4.013

Review 3.  Role of oxidized low density lipoprotein in atherogenesis.

Authors:  J L Witztum; D Steinberg
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

4.  Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene.

Authors:  S L Schissel; E H Schuchman; K J Williams; I Tabas
Journal:  J Biol Chem       Date:  1996-08-02       Impact factor: 5.157

5.  Effects of dietary supplementation with marine lipid concentrate on the plasma lipoprotein composition of hypercholesterolemic patients.

Authors:  P V Subbaiah; M H Davidson; M C Ritter; W Buchanan; J D Bagdade
Journal:  Atherosclerosis       Date:  1989-10       Impact factor: 5.162

6.  Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein. A deep-etch and immunolocalization study of ultrarapidly frozen tissue.

Authors:  P F Nievelstein; A M Fogelman; G Mottino; J S Frank
Journal:  Arterioscler Thromb       Date:  1991 Nov-Dec

7.  Free cholesterol loading of macrophages stimulates phosphatidylcholine biosynthesis and up-regulation of CTP: phosphocholine cytidylyltransferase.

Authors:  Y Shiratori; A K Okwu; I Tabas
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

8.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.

Authors:  A S Plump; J D Smith; T Hayek; K Aalto-Setälä; A Walsh; J G Verstuyft; E M Rubin; J L Breslow
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

9.  Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction.

Authors:  P V Subbaiah; M Liu
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

10.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.

Authors:  S H Zhang; R L Reddick; J A Piedrahita; N Maeda
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

View more
  44 in total

1.  Effect of liver total sphingomyelin synthase deficiency on plasma lipid metabolism.

Authors:  Zhiqiang Li; Yeun-Po Chiang; Mulin He; Ke Zhang; Jiao Zheng; Weihua Wu; Jiajia Cai; Yong Chen; Guangzhi Chen; Yunqin Chen; Jibin Dong; Tilla S Worgall; Xian-Cheng Jiang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2021-02-02       Impact factor: 4.698

2.  Pharmacological Activation of Peroxisome Proliferator-Activated Receptor {Delta} Increases Sphingomyelin Synthase Activity in THP-1 Macrophage-Derived Foam Cell.

Authors:  Dongsheng Mou; Hua Yang; Changhua Qu; Juan Chen; Chaogui Zhang
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

3.  Lamellar lipoproteins uniquely contribute to hyperlipidemia in mice doubly deficient in apolipoprotein E and hepatic lipase.

Authors:  N Bergeron; L Kotite; M Verges; P Blanche; R L Hamilton; R M Krauss; A Bensadoun; R J Havel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  Regulation of plasma cholesterol esterification by sphingomyelin: effect of physiological variations of plasma sphingomyelin on lecithin-cholesterol acyltransferase activity.

Authors:  Papasani Venkata Subbaiah; Xian-Cheng Jiang; Natalia A Belikova; Buzulagu Aizezi; Zhi Hua Huang; Catherine A Reardon
Journal:  Biochim Biophys Acta       Date:  2012-02-18

5.  Selective reduction in the sphingomyelin content of atherogenic lipoproteins inhibits their retention in murine aortas and the subsequent development of atherosclerosis.

Authors:  Yifan Fan; Fujun Shi; Jing Liu; Jibin Dong; Hai H Bui; David A Peake; Ming-Shang Kuo; Guoqing Cao; Xian-Cheng Jiang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-09-02       Impact factor: 8.311

6.  Diet-induced lipid accumulation in phospholipid transfer protein-deficient mice: its atherogenicity and potential mechanism.

Authors:  Calvin Yeang; Shucun Qin; Kailian Chen; David Q-H Wang; Xian-Cheng Jiang
Journal:  J Lipid Res       Date:  2010-06-11       Impact factor: 5.922

7.  Sphingomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice.

Authors:  Jing Liu; Hongqi Zhang; Zhiqiang Li; Tiruneh K Hailemariam; Mahua Chakraborty; Kailiu Jiang; Daniel Qiu; Hai H Bui; David A Peake; Ming-Shang Kuo; Raj Wadgaonkar; Guoqing Cao; Xian-Cheng Jiang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03-12       Impact factor: 8.311

Review 8.  Roles and regulation of secretory and lysosomal acid sphingomyelinase.

Authors:  Russell W Jenkins; Daniel Canals; Yusuf A Hannun
Journal:  Cell Signal       Date:  2009-06       Impact factor: 4.315

9.  Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins.

Authors:  Maxwell A Ruby; Daniel K Nomura; Carolyn S S Hudak; Lara M Mangravite; Sally Chiu; John E Casida; Ronald M Krauss
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-15       Impact factor: 11.205

Review 10.  Ceramide: a common pathway for atherosclerosis?

Authors:  Jean Bismuth; Peter Lin; Qizhi Yao; Changyi Chen
Journal:  Atherosclerosis       Date:  2007-10-25       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.